Keros Therapeutics (KROS) Change in Account Payables (2019 - 2025)

Keros Therapeutics (KROS) has 7 years of Change in Account Payables data on file, last reported at -$697000.0 in Q4 2025.

• Quarterly Change in Account Payables fell 137.88% year-over-year to -$697000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$3.0 million (down 1105.22% YoY) and the FY2025 annual result came in at -$3.0 million, down 1105.22% from the prior year.
• Change in Account Payables advanced to -$697000.0 in Q4 2025, from -$3.0 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $4.7 million in Q2 2022 to a low of -$5.0 million in Q3 2022.
• A 5-year average of -$27950.0 and a median of -$79500.0 in 2023 frame the typical range for Change in Account Payables.
• Annual changes were most pronounced in 2024 — Change in Account Payables sank 774.73% — and 2025, when it jumped 8678.26%.
• Tracing KROS's Change in Account Payables over 5 years: stood at $823000.0 in 2021, then retreated by 27.7% to $595000.0 in 2022, then jumped by 75.46% to $1.0 million in 2023, then plunged by 128.07% to -$293000.0 in 2024, then tumbled by 137.88% to -$697000.0 in 2025.
• The last three Change in Account Payables figures came in at -$697000.0 (Q4 2025), -$3.0 million (Q3 2025), and -$1.4 million (Q2 2025), per Business Quant data.